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Background
Equine viral arteritis (EVA) has become a very
important issue in the equine industry since the
occurrence of a disease outbreak in the Quarter
Horse breeding industry in 2006. Equine viral
arteritis is a contagious disease syndrome caused by
the Equine Arteritis Virus (EAV), which can infect
all equines. Although EVA generally causes only
mild upper respiratory tract disease in adult horses,
it can cause fatal pneumonia in young foals and
abortion in pregnant mares. In addition, stallions
infected with EAV may become persistently
infected sub-clinically (i.e., without evidence of
infection) and shed infectious virus in their semen
(i.e., become virus “carriers”). Transmission of the
virus can occur via contact with respiratory
secretions of clinically ill animals; contact with an
aborted fetus and its associated fetal
membranes/fluids; and/or contact with semen from
a chronically infected stallion. Particularly
important is the potential for widespread
dissemination of the virus associated with the use of
cooled and/or frozen semen (Figure 1) from
chronically infected stallions, which was the
principal mode of transmission in the Quarter Horse
industry in 2006. That outbreak has lead to
increased recognition of the disease, and prompted
federal and state regulatory agencies and the
breeding industry to take a heightened approach to
control measures for EVA. Current recommendations focus on minimizing the risk of exposure that
would lead to the introduction of the virus into

susceptible groups of horses; vaccination of
susceptible, “at-risk” horses (e.g., broodmares); and
prevention of the disease in naive stallions in order
to avoid the persistently infected carrier state.
Clinical Signs
In otherwise healthy adult horses, clinical signs of
EAV infection may not be evident. When clinical
signs do occur, they typically become evident 3 to 7
days post-exposure and may include: fever;

Figure 1. Typical cooled semen transport
containers. Photo from Equitainer.

depression; anorexia; dependent edema of the limbs
and ventral abdomen; urticaria; supra or periorbital
edema; conjunctivitis; lacrimal discharge and serous
to mucoid nasal discharge. Infection in unprotected
pregnant mares frequently leads to abortion. Young
foals can develop severe, life-threatening
pneumonia.

Diagnosis
Since the clinical signs of EVA are similar to other
causes of respiratory diseases (e.g., influenza), EVA
should be considered in any horse showing signs of
respiratory disease. Similarly, EVA should be
considered in any mare that aborts her pregnancy.
Virus isolation can be attempted from swabs of
nose, throat or eyes; or in the case of abortion, the
aborted fetus, fetal fluids or placenta. The most
common method of diagnosing EVA is by
performing serology testing of blood for EAV
neutralizing antibodies. Although the presence of
neutralizing antibodies does not indicate active
infection, it does indicate exposure to EAV has
occurred. Extremely high antibody levels in a single
sample or a four-fold or greater rise in antibody
level in paired samples collected 14 to 28 days apart
are generally indicative of recent active infection.
Treatment
There is no specific treatment of EVA, so efforts are
directed at supportive care, such as rest and the use
of anti-inflammatory medication to reduce a fever.
Prevention and Control
First and foremost, it is important to know the EAV
status of resident stallions and/or stallions at other
locations that will be used for breeding purposes
(e.g., shipped or frozen semen). Serology can be
used to assess prior exposure of a stallion to EAV;
however, serology cannot distinguish between
natural infection (that may have induced a “carrier”
state in the stallion) or prior vaccination against
EAV. Stallions that are seronegative (titer <1:4) are
not infective and mares can be bred to these
stallions without risk of infection. Owners of
seronegative stallions should strongly consider
vaccinating the stallion to prevent the possibility of
infection in the future with its attendant risk of
development of the carrier state. Vaccination should
be done at least 28 days prior to breeding/semen
collection. Because serology cannot distinguish
between natural infection and vaccination, it is
imperative to have permanent documentation that a
stallion was tested and shown to be seronegative
prior to vaccination.
Seropositive stallions (titer >1:4), that have no
record of having been seronegative prior to

vaccination, should have their semen tested to
determine if they are persistently infected. Testing
involves examining an ejaculate of semen for the
presence of EAV by the accredited laboratory at the
Gluck Equine Research Center at the University of
Kentucky
(http://www2.ca.uky.edu/gluck/serveva.asp).
Seropositive shedding stallions must be managed
appropriately, which involves breeding only to
vaccinated/seropositive mares and recognizing that
all materials that come in contact with the stallion’s
semen are potentially infective. Vaccinated mares
should be isolated for 21 days following their first
breeding to a carrier stallion, because these mares
may become transiently viremic with “wild-type”
virus after breeding. Isolation for 21 days is not
necessary after subsequent breeding, though
isolation for at least 24 hours should be performed
after every breeding to prevent mechanical spread
of EAV if semen is voided from the mare’s
reproductive tract. Because of the severe health risk
of EVA in young foals, breeding post-partum mares
(even if vaccinated) to EAV shedding stallions
should be avoided, because of the potential for
transmission of the virus to the mare’s foal.
It is important to note that
vaccinating horses against EVA
is done using a modified-live
virus vaccine, which can be shed
post-vaccination (causing other
horses to seroconvert); therefore,
horses should be isolated for at
least 21 days after administration
of the vaccine.
Many states have adopted
statutory language governing the
prevention and control of EVA.
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breeding entering Utah be tested
for Equine Viral Arteritis by an
accredited veterinarian within 30 days prior to entry
by rule (R58-23). Exceptions to the above are
stallions that have proof of negative EVA status
prior to vaccination and proof of subsequent yearly
vaccination. No EVA carrier stallion used for
breeding purposes shall be permitted to enter Utah
without a prior permit from the State Veterinarian.
No semen from a carrier stallion shall be permitted
to enter into Utah without a prior permit from the

State Veterinarian. All EVA Carrier Stallions, used
for breeding purposes, imported into Utah shall be
taken directly to an approved facility and shall
remain on said facility until permission from the
State Veterinarian is obtained to move the animal to
another approved facility. All semen from an EVA
Carrier Stallion imported into Utah shall be shipped
directly to an approved facility and shall remain on
said facility until inseminated, transported to
another approved facility and/or disposed of.

The private veterinary practitioner immediately
upon receiving a positive laboratory report on EVA
shall report all EVA positive equids to the State
Veterinarian. All EVA positive test results
processed at a state owned laboratory shall be
immediately reported to the State Veterinarian. The
State Veterinarian may require testing of any
stallion suspected of being exposed to EAV.

All stallions used for breeding purposes identified
as EVA positive shall have their semen tested by an
accredited veterinarian at an approved laboratory
prior to breeding. All carrier stallions used for
breeding purposes shall be housed and maintained
at an approved facility until permission from the
State Veterinarian is given to move the stallion to
another approved facility. All EVA infected semen
shall only be collected, handled, evaluated,
received, packaged and/or administered at an
approved facility.

Equine viral arteritis is now recognized as an
important health threat in the equine industry,
particularly in animals used for breeding. Through
appropriate control and prevention procedures, such
as serological testing and vaccination, the risk of
EVA can be minimized. An important strategy for
controlling EVA is prevention of the persistently
infected carrier state in stallions. Because of the
regulatory aspect of EVA, it is imperative that horse
owners contact their respective states’ regulatory
authority for information regarding rules in place
that govern the control of EVA.

All equids, including but not limited to stallions,
mares and geldings, on approved facilities shall be
vaccinated for EVA no less than 21 days before the
start of breeding season or no less than 21 days
before arriving at an approved facility. Mares being
bred to a carrier stallion, or inseminated with semen
from a carrier stallion, shall remain on the approved
facility for a minimum of 21 days after the initial
breeding date. Adequate biosecurity precautions
shall be in place during the breeding season. The
adequacy of biosecurity may be monitored
periodically by the Utah Department of Agriculture
and Food.

Summary

Additional Information
The United States Department of Agriculture
(USDA), Animal and Plant Health Inspection
Service (APHIS), Veterinary Services (VS) has
several information resources about EVA that are
available online at:
http://www.aphis.usda.gov/animal_health/animal_di
seases/eva/
The American Association of Equine Practitioners
(AAEP) has a fact sheet on EVA that can be
accessed online at: http://www.aaep.org/eva.htm
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